0001493152-23-031363.txt : 20230831 0001493152-23-031363.hdr.sgml : 20230831 20230831172739 ACCESSION NUMBER: 0001493152-23-031363 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230828 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230831 DATE AS OF CHANGE: 20230831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIRA PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001904286 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 853354547 STATE OF INCORPORATION: FL FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41765 FILM NUMBER: 231229835 BUSINESS ADDRESS: STREET 1: 855 N WOLFE STREET #623-6 CITY: BALTIMORE STATE: MD ZIP: 21205 BUSINESS PHONE: 813-369-5150 MAIL ADDRESS: STREET 1: 324 SOUTH HYDE PARK AVENUE, SUITE 350 CITY: TAMPA STATE: FL ZIP: 33606 FORMER COMPANY: FORMER CONFORMED NAME: Mira1a Therapeutics, Inc. DATE OF NAME CHANGE: 20220112 8-K 1 form8-k.htm
0001904286 false 0001904286 2023-08-28 2023-08-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 28, 2023

 

 

 

MIRA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Florida   001-41765   85-3354547

(State or Other Jurisdiction of

Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

855 N Wolfe Street, Suite 601

Baltimore, Maryland

  21205
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (737) 289-0835

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   MIRA   The Nasdaq Capital Market

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 28, 2023, MIRA Pharmaceuticals, Inc. (the “Company”) entered into an Amendment to Employment Agreement with Erez Aminov, the Company’s Chief Executive Officer, pursuant to which Mr. Aminov’s annual base salary was increased to $200,000 per annum effective as of August 28, 2023, and pursuant to which Mr. Aminov became entitled to an additional payment equal to the amount he would have received if his initial base salary were $200,000 per annum beginning August 1, 2023.

 

Also on August 28, 2023, the Company entered into an Amendment to Employment with Dr. Chris Chapman, the Company’s Executive Chairman, clarifying that Dr. Chapman’s employment with the Company is on a part-time, as-needed basis.

 

The Amendment to Employment Agreement with Mr. Aminov and the Amendment to Employment Agreement with Dr. Chapman are attached as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K, and the descriptions of such agreements contained herein are summary in nature and are qualified in their entirety by reference to the full text of such agreements.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

No.

   Description
     
10.1   Amendment to Employment Agreement, August 28, 2023, between MIRA Pharmaceuticals, Inc. and Erez Aminov.
10.2   Amendment to Employment Agreement, dated August 28, 2023, between MIRA Pharmaceuticals and Dr. Chris Chapman.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

   

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MIRA PHARMACEUTICALS, INC.
     
Date, August 31, 2023 By: /s/ Michelle Yanez                
    Michelle Yanez
    Chief Financial Officer

 

   

  

 EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

AMENDMENT TO EMPLOYMENT AGREEMENT

 

This Amendment to Employment Agreement, dated August 28, 2023 (this “Amendment), amends that certain Employment Agreement, dated April 28, 2023, (the “Agreement”), between Erez Aminov (“Employee”) and MIRA Pharmaceuticals, Inc. (the “Company”). The Employee and Company may hereinafter be referred to individually as a “Party” and collectively as (the “Parties”).

 

RECITALS

 

WHEREAS, the original Agreement was entered into on April 28, 2023, which sets forth the terms and conditions of employment between the Employee and the Company; and

 

WHEREAS, the Company and Employee hereby desire to amend the Agreement to modify Section 3 thereof.

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

 

1. AMENDMENT TO COMPENSATION CLAUSE, SECTION 3 OF THE AGREEMENT:

 

Section 3 of the Agreement is hereby deleted in its entirety and replaced with the following:

 

“Compensation. The Company shall pay Employee an initial base salary of $200,000 per annum effective as of August 28, 2023, and will make an additional payment to Employee of the salary that would have been payable to him as though his base salary were $200,000 per annum beginning as of August 1, 2023. The Employee’s Base Salary shall be paid monthly after the deduction of appropriate federal, state, and local withholding taxes. Bonus Compensation may be paid to Employee in the discretion of the Company’s Board of Directors, including at its annual review of Employee’s compensation.”

 

2. EFFECT OF AMENDMENT:

 

Except as specifically amended hereby, all other provisions, terms, and conditions of the Agreement shall remain in full force and effect. In the event of any conflict between the provisions of the Agreement and this Amendment, the provisions of this Amendment shall govern.

 

3. ENTIRE AGREEMENT: This Amendment and the Agreement contain the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior negotiations, understandings, and agreements between the Parties with respect to the subject matter hereof.

 

   

 

 

4. GOVERNING LAW; SEVERABILITY:

 

This Amendment will be governed by and construed in accordance with the laws of the State of Florida, without giving effect to that body of laws pertaining to conflict of law. If any provision of this Amendment is determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Amendment and the remainder of this Amendment shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been contained in this Amendment. Notwithstanding the foregoing, if the value of this Amendment based upon the substantial benefit of the bargain for any Party is materially impaired, which determination as made by the presiding court or arbitrator of competent jurisdiction shall be binding, then this Amendment will not be enforceable against such affected Party and both Parties agree to renegotiate such provision(s) in good faith.

 

COUNTERPARTS:

 

This Amendment may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including ..pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

 

IN WITNESS WHEREOF, the Parties have entered into this Amendment as of the day and year first written above.

 

  MIRA PHARMACEUTICALS, INC.
   
     
  By: Michelle Yanez
  Title: Chief Financial Officer
     
     
    Erez Aminov, individually

 

   

 

 EX-10.2 3 ex10-2.htm

 

Exhibit 10.2

 

AMENDMENT TO EMPLOYMENT AGREEMENT

 

This Amendment to Employment Agreement, dated August 28, 2023 (this “Amendment), amends that certain Employment Agreement, dated April 28, 2023 (the “Agreement”), between Chris Chapman (“Employee”) and MIRA Pharmaceuticals, Inc. (the “Company”). The Employee and Company may hereinafter be referred to individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

WHEREAS, the original Agreement was entered into on April 28, 2023, which sets forth the terms and conditions of employment between the Employee and the Company; and

 

WHEREAS, the Company and Employee hereby desire to amend the Agreement to clarify and modify Section 1(c) thereof.

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

 

1. AMENDMENT TO POSITION OF EMPLOYMENT CLAUSE, SECTION 1(c) OF THE AGREEMENT:

 

Section 1(c) of the Agreement is hereby deleted in its entirety and replaced with the following:

 

“Employee shall devote his business time and effort to the business and affairs of the Company on a part-time, as needed basis. The Company acknowledges that Employee is currently engaged in activities and consultancies in addition to Employee’s employment relationship with the Company, and that Employee may establish additional outside relationships and activities without approval by the Company so long as they do not unreasonably interfere with Employee’s duties hereunder.”

 

2. EFFECT OF AMENDMENT:

 

Except as specifically amended hereby, all other provisions, terms, and conditions of the Agreement shall remain in full force and effect. In the event of any conflict between the provisions of the Agreement and this Amendment, the provisions of this Amendment shall govern.

 

3. ENTIRE AGREEMENT: This Amendment and the Agreement contain the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior negotiations, understandings, and agreements between the Parties with respect to the subject matter hereof.

 

4. GOVERNING LAW; SEVERABILITY:

 

This Amendment will be governed by and construed in accordance with the laws of the State of Florida, without giving effect to that body of laws pertaining to conflict of law. If any provision of this Amendment is determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Amendment and the remainder of this Amendment shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been contained in this Amendment. Notwithstanding the foregoing, if the value of this Amendment based upon the substantial benefit of the bargain for any Party is materially impaired, which determination as made by the presiding court or arbitrator of competent jurisdiction shall be binding, then this Amendment will not be enforceable against such affected Party and both Parties agree to renegotiate such provision(s) in good faith.

 

   

 

 

5. COUNTERPARTS:

 

This Amendment may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including ..pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

IN WITNESS WHEREOF, the Parties have entered into this Amendment as of the day and year first written above.

 

  MIRA PHARMACEUTICALS, INC.
   
     
  By: Michelle Yanez
  Title: Chief Financial Officer
     
     
    Chris Chapman, individually

 

   

 

 EX-101.SCH 4 mira-20230828.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mira-20230828_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 6 mira-20230828_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 28, 2023
Entity File Number 001-41765
Entity Registrant Name MIRA PHARMACEUTICALS, INC.
Entity Central Index Key 0001904286
Entity Tax Identification Number 85-3354547
Entity Incorporation, State or Country Code FL
Entity Address, Address Line One 855 N Wolfe Street
Entity Address, Address Line Two Suite 601
Entity Address, City or Town Baltimore
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21205
City Area Code (737)
Local Phone Number 289-0835
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol MIRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Entity Information, Former Legal or Registered Name Not Applicable
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001904286 2023-08-28 2023-08-28 iso4217:USD shares iso4217:USD shares 0001904286 false 8-K 2023-08-28 MIRA PHARMACEUTICALS, INC. FL 001-41765 85-3354547 855 N Wolfe Street Suite 601 Baltimore MD 21205 (737) 289-0835 Not Applicable false false false false Common Stock, $0.0001 par value per share MIRA NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

P/ !?JQ"(6,P$ "(" / M " =40 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !S MBQ]7)!Z;HJT #X 0 &@ @ $U$@ >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !SBQ]799!YDAD! #/ P $P M @ $:$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" !D% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://mirapharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex10-1.htm ex10-2.htm mira-20230828.xsd mira-20230828_lab.xml mira-20230828_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "mira-20230828_lab.xml" ] }, "presentationLink": { "local": [ "mira-20230828_pre.xml" ] }, "schema": { "local": [ "mira-20230828.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mira", "nsuri": "http://mirapharmaceuticals.com/20230828", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://mirapharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mirapharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-031363-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-031363-xbrl.zip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